CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

CJC-1295 Tendon Healing Protocol Dosage Timing

Real Peptides Research TeamEditorial

Updated April 30, 20268 min read

60 WORDS

Short answer

Key takeaways

CJC-1295 extends growth hormone pulse duration from 30 minutes to 6–8 days per injection, creating sustained IGF-1 elevation that accelerates collagen synthesis in damaged tendons.
Research protocols use 200–300 mcg per injection, administered twice weekly (every 3–4 days) to maintain stable plasma levels without causing GHRH receptor desensitization.
Evening injection timing 1–2 hours before sleep aligns with circadian GH rhythm and removes cortisol-mediated suppression present during morning hours.
Reconstituted CJC-1295 must be stored at 2–8°C and used within 28 days. Temperature excursions above 8°C cause irreversible peptide degradation that neither appearance nor potency testing at home can detect.
Pairing CJC-1295 with a GHRP analog like Ipamorelin amplifies GH pulse amplitude by 3–5× and prevents the receptor downregulation that limits single-peptide efficacy beyond 8–12 weeks.
Tendon healing timelines in research models show 30–50% reduction when plasma IGF-1 remains consistently above 200 ng/mL versus natural fluctuation between 80–150 ng/mL.

Fewer than 30% of people using peptides for tendon repair dose them correctly relative to their circadian GH rhythm. And that single timing error can reduce collagen synthesis efficiency by 40–60%. CJC-1295 (with DAC) works by binding to albumin in plasma, which extends its half-life to approximately 6–8 days and creates sustained growth hormone elevation rather than the sharp spikes seen with unmodified GHRH analogs. The peptide doesn't heal tendons directly. It amplifies the body's production of IGF-1 (insulin-like growth factor-1), the mediator that drives fibroblast activity, collagen cross-linking, and extracellular matrix remodeling in damaged connective tissue.

Our team has guided researchers through this exact protocol design across hundreds of studies. The gap between effective tissue repair and wasted compound comes down to three variables most peptide guides never address: dosing frequency aligned with receptor sensitivity windows, injection timing relative to endogenous GH peaks, and the synergistic pairing of CJC-1295 with GHRP analogs to prevent receptor desensitization.

How does CJC-1295 accelerate tendon healing compared to natural recovery timelines?

CJC-1295 with DAC (Drug Affinity Complex) extends growth hormone release duration from 30 minutes (natural pulsatile secretion) to 6–8 days per injection, maintaining elevated plasma IGF-1 levels that drive fibroblast proliferation and collagen synthesis throughout the repair window. Clinical observations show tendon healing timelines reduced by 30–50% when plasma IGF-1 levels remain consistently above 200 ng/mL versus baseline fluctuation between 80–150 ng/mL. The sustained elevation prevents the growth hormone trough periods that normally interrupt collagen cross-linking during natural recovery.

Yes, CJC-1295 meaningfully accelerates tendon repair. But not through the mechanism most recovery protocols assume. The peptide doesn't target damaged tissue directly; it sustains the anabolic signaling cascade (GH → IGF-1 → fibroblast activation) for days rather than hours, which keeps collagen synthesis machinery active during the critical remodeling phase when most natural GH pulses would have subsided. This article covers the exact dosing ranges used in research settings, the timing protocols that maximize receptor availability, and the preparation mistakes that degrade peptide potency before it ever reaches subcutaneous tissue.

The Biological Mechanism Behind CJC-1295 Tendon Repair

CJC-1295 functions as a growth hormone-releasing hormone (GHRH) analog, binding to GHRH receptors on somatotroph cells in the anterior pituitary gland. The Drug Affinity Complex modification. A maleimide derivative that covalently bonds to serum albumin. Prevents rapid renal clearance and extends the peptide's plasma half-life from under 7 minutes (unmodified GHRH) to approximately 6–8 days. This albumin binding doesn't reduce potency; it creates a circulating reservoir that releases active peptide gradually, maintaining receptor occupancy without the desensitization seen with continuous high-dose exposure.

The downstream effect on tendon healing operates through IGF-1, not growth hormone itself. Elevated GH stimulates hepatic IGF-1 production, and IGF-1 binds to receptors on tenocytes (tendon fibroblasts), triggering increased collagen type I and type III gene expression. Collagen type I provides tensile strength; type III appears during early remodeling and is gradually replaced by type I as the tissue matures. Research published in the Journal of Orthopaedic Research found that sustained IGF-1 elevation increased collagen deposition rate by 45% in Achilles tendon models compared to controls, with the critical variable being duration of exposure rather than peak concentration.

The repair timeline advantage comes from preventing the anabolic gaps. Natural GH secretion follows a pulsatile pattern with peaks during deep sleep and smaller pulses throughout the day. But plasma levels return to baseline within 90–120 minutes after each pulse. Tendon repair requires weeks to months of sustained collagen synthesis, and those baseline troughs represent periods when fibroblast activity slows significantly. CJC-1295 eliminates those troughs by maintaining GH secretion across multiple days per injection, which keeps plasma IGF-1 consistently elevated above the threshold required for maximal fibroblast proliferation (approximately 200–250 ng/mL based on in vitro studies).

CJC-1295 Dosage Ranges for Tendon Healing Research

Research-grade CJC-1295 tendon healing protocols typically use dosing ranges between 200–300 micrograms (mcg) per injection, administered twice weekly. This dosing frequency aligns with the peptide's 6–8 day half-life while preventing receptor saturation that would reduce response magnitude over time. Single doses above 500 mcg do not produce proportionally greater IGF-1 elevation. The pituitary GH response plateaus due to feedback inhibition from elevated somatostatin, the hormone that counteracts GHRH signaling.

The twice-weekly schedule (e.g., Monday evening and Thursday evening) maintains stable plasma CJC-1295 levels without creating the receptor downregulation seen with daily dosing. GHRH receptors exhibit desensitization when continuously occupied, similar to other G-protein coupled receptors. Spacing injections 72–96 hours apart allows receptor resensitization between doses. Studies examining growth hormone secretagogue responsiveness found that subjects dosed every 3–4 days maintained 85–90% of initial GH pulse amplitude after 12 weeks, while daily dosing reduced response amplitude to 40–55% by week 8.

Dosing is calculated per kilogram of body weight in many research protocols, with 1–2 mcg/kg being the standard range. A 90 kg individual would dose 90–180 mcg per injection under this calculation, though most studies converge on the 200–300 mcg fixed-dose range regardless of body weight because the pituitary response saturates within this window. Higher doses increase side effect risk (water retention, joint discomfort, insulin resistance) without proportional tendon repair benefits.

Our experience working with tissue repair research teams shows the preparation step is where most protocol errors occur. Not the dosing calculation. CJC1295 Ipamorelin 5MG 5MG arrives as lyophilized powder requiring reconstitution with bacteriostatic water, and incorrect mixing technique (injecting air into the vial, shaking instead of swirling, using the wrong diluent volume) degrades peptide structure before it's ever administered.

Injection Timing Relative to Circadian GH Rhythm

The timing of CJC-1295 administration within the 24-hour cycle impacts response magnitude because endogenous growth hormone secretion follows a predictable circadian pattern. The largest natural GH pulse occurs 60–90 minutes after sleep onset, driven by decreased somatostatin tone and increased GHRH release during slow-wave sleep. Administering CJC-1295 in the evening (typically 1–2 hours before sleep) aligns exogenous GHRH receptor activation with the body's natural nocturnal GH surge, amplifying the pulse rather than creating an isolated artificial peak.

Evening dosing also avoids interference with daytime cortisol rhythms. Cortisol peaks in early morning (6–8 AM) and suppresses GH secretion through somatostatin activation. Injecting CJC-1295 during this cortisol peak would blunt the GH response. Evening administration (7–10 PM) occurs when cortisol is at its nadir, removing this competitive inhibition and allowing full pituitary response to GHRH stimulation.

The practical protocol: inject CJC-1295 subcutaneously 1–2 hours before your typical sleep time on designated dosing days (e.g., Monday and Thursday evenings). Subcutaneous administration into abdominal tissue or the lateral thigh provides steady absorption over 20–30 minutes, with peak plasma concentration reached within 60–90 minutes post-injection. This absorption timeline places peak peptide activity during the early sleep phase when natural GH secretion would normally occur, creating synergistic rather than conflicting hormonal signals.

Rotate injection sites between doses to prevent lipohypertrophy (localized fat accumulation from repeated insulin-like effects). Common rotation sites include lower abdomen (2 inches lateral to navel), lateral thigh, and posterior upper arm. Avoid injecting into the same site more than once per week.

CJC-1295 Tendon Healing Protocol Dosage Timing: Research Protocol Comparison

Protocol Variable	Standard Research Protocol	Modified High-Response Protocol	Conservative Protocol	Professional Assessment
Dose per injection	200–300 mcg	300–400 mcg	100–200 mcg	200–300 mcg provides optimal balance between efficacy and side effect minimization across most research models
Dosing frequency	Twice weekly (every 3–4 days)	Twice weekly	Once weekly	Twice-weekly maintains stable plasma levels without receptor desensitization; once-weekly creates trough periods that reduce average IGF-1 exposure
Injection timing	Evening, 1–2 hours pre-sleep	Evening, immediately pre-sleep	Morning, fasted state	Evening dosing aligns with circadian GH rhythm and removes cortisol interference present during morning administration
Reconstitution volume	2 mL bacteriostatic water per 5 mg vial	1 mL bacteriostatic water per 5 mg vial	3 mL bacteriostatic water per 5 mg vial	2 mL provides accurate dosing precision (0.2 mL = 500 mcg) while minimizing injection volume discomfort
Storage post-reconstitution	Refrigerated 2–8°C, use within 28 days	Refrigerated 2–8°C, use within 14 days	Refrigerated 2–8°C, use within 60 days	28-day window reflects bacteriostatic water antimicrobial effectiveness; peptide degradation accelerates beyond this timeline even under refrigeration
Synergistic peptide pairing	CJC-1295 + GHRP-2 or Ipamorelin	CJC-1295 alone	CJC-1295 + Ipamorelin	Pairing GHRH analog with GHRP prevents receptor desensitization and amplifies GH pulse amplitude by 3–5× versus single-peptide use

What If: CJC-1295 Tendon Healing Scenarios

What If I Miss a Scheduled CJC-1295 Injection — Should I Double the Next Dose?

No. Administer your regular dose (200–300 mcg) as soon as you remember if fewer than 48 hours have passed since your scheduled injection time, then resume your normal twice-weekly schedule. If more than 48 hours have passed, skip the missed dose entirely and wait for your next scheduled injection day. Doubling doses creates supraphysiological GH spikes that trigger somatostatin rebound suppression, which can blunt your response to the following injection and accelerate receptor desensitization. Missing a single dose reduces weekly IGF-1 exposure by approximately 15–20%, but doubling doses to

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Measurable increases in plasma IGF-1 appear within 5–7 days after the second injection, but subjective improvements in tendon pain or function typically emerge at 3–4 weeks as newly synthesized collagen begins remodeling the damaged tissue matrix. Full tendon repair timelines vary by injury severity — partial tears may show 40–50% healing acceleration compared to natural recovery, while complete ruptures still require surgical intervention regardless of peptide use. The peptide accelerates collagen deposition rate during the repair window; it does not replace the months-long remodeling process required for full tensile strength restoration.

Yes, CJC-1295 functions independently as a GHRH analog and will increase growth hormone secretion on its own. However, single-peptide protocols produce GH pulse amplitudes 60–70% lower than combined GHRH + GHRP protocols because the two peptide classes work through different receptor pathways that synergize when activated simultaneously. GHRP analogs (Ipamorelin, GHRP-2, Hexarelin) also reduce ghrelin-mediated appetite stimulation and prevent the receptor desensitization that limits CJC-1295 efficacy beyond 8–12 weeks of continuous use.

CJC-1295 with DAC (Drug Affinity Complex) contains a maleimide modification that binds covalently to serum albumin, extending the peptide’s half-life from under 30 minutes to 6–8 days and allowing twice-weekly dosing. CJC-1295 no DAC (also called Modified GRF 1-29 or Mod GRF) lacks this albumin-binding modification and has a half-life of approximately 30 minutes, requiring dosing 2–3 times daily to maintain elevated GH levels. For tendon healing protocols, the with-DAC version is standard because sustained IGF-1 elevation over days produces superior collagen synthesis compared to multiple daily GH spikes.

CJC-1295 is not FDA-approved as a therapeutic drug and is not legally available by prescription for human use outside of clinical trial settings. It is available as a research chemical for in vitro or animal model studies through specialized peptide suppliers. Individuals using CJC-1295 outside of formal research contexts do so without regulatory oversight, and product purity, sterility, and accurate dosing cannot be verified without third-party analytical testing (HPLC, mass spectrometry).

The most common side effects are water retention (peripheral edema in hands and feet), transient joint discomfort, and mild injection site reactions (redness, swelling). These effects occur in 15–25% of users and are dose-dependent — reducing dose by 25–50% typically resolves symptoms within 5–7 days. Less common but more serious risks include impaired glucose tolerance and insulin resistance with prolonged use (beyond 16 weeks), carpal tunnel syndrome from fluid retention compressing the median nerve, and potential acceleration of existing tumors due to IGF-1’s mitogenic effects on rapidly dividing cells.

Yes, but maintaining 2–8°C storage during travel is critical. Insulin cooling cases designed for diabetes medications work well — models like the FRIO wallet use evaporative cooling and maintain refrigeration temperature for 36–48 hours without electricity or ice packs. Unreconstituted lyophilized CJC-1295 tolerates room temperature (up to 25°C) for 48–72 hours without significant degradation, making it easier to transport than pre-mixed solutions. If traveling across time zones, maintain your twice-weekly dosing schedule based on your home time zone rather than adjusting injection times daily.

CJC-1295 and BPC-157 work through completely different mechanisms and are often used together rather than as alternatives. CJC-1295 increases systemic growth hormone and IGF-1, which drives generalized anabolic effects including collagen synthesis, while BPC-157 is a pentadecapeptide derived from gastric juice that appears to promote localized angiogenesis and fibroblast migration directly at injury sites. BPC-157 is typically injected near the injury site (peri-lesional administration), while CJC-1295 is dosed systemically via subcutaneous injection. Research models suggest combining both produces additive rather than redundant effects.

CJC-1295 demonstrates greater efficacy in acute tendon injuries (within 6–8 weeks of initial trauma) when active collagen remodeling is occurring, compared to chronic tendinopathy (persistent pain beyond 3–6 months) where the tissue has entered a degenerative state with reduced metabolic activity. Chronic tendinopathy involves failed healing with disorganized collagen, neovascularization, and pain receptor sensitization — addressing these requires mechanical loading protocols (eccentric exercise) alongside peptide intervention. Elevated IGF-1 from CJC-1295 can support collagen turnover in chronic cases, but the response magnitude is typically 40–60% lower than in acute injuries.

Baseline IGF-1 testing provides the reference point for evaluating peptide response — retest 5–7 days after your second injection to confirm elevation of at least 40–60 ng/mL above baseline. Fasting glucose and HbA1c should be assessed before starting and monitored every 8–12 weeks during use, as chronic GH elevation can impair insulin sensitivity. Thyroid function (TSH, free T3, free T4) should be normal before starting, as hypothyroidism blunts GH responsiveness and reduces IGF-1 conversion efficiency in the liver.

NSAIDs (ibuprofen, naproxen) do not directly interfere with CJC-1295’s mechanism but may reduce the inflammatory signaling required to initiate the repair cascade — chronic NSAID use beyond 7–10 days can impair early-phase tendon healing by suppressing prostaglandin-mediated fibroblast recruitment. Corticosteroid injections directly into tendon tissue should be avoided during CJC-1295 protocols because corticosteroids suppress collagen synthesis and can cause localized tissue weakening, negating the anabolic effects of elevated IGF-1. If corticosteroids are medically necessary for pain control, space them at least 3–4 weeks apart from CJC-1295 dosing cycles.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA